Cullinan's deal for T cell engager from China; Kardigan buys late-stage heart...
Plus, news about Novartis, Signify Bio, Ocugen, Dynavax and ViGeneron: Cullinan Therapeutics gets rights to T cell engager developed in China: The company made a deal with Chongqing-based Genrix Bio...
View ArticleFDA's Prasad details decision to pause chikungunya vaccine in seniors
The FDA and CDC's decision last month to pause administering Valneva's live-attenuated chikungunya vaccine in patients 60 and older was meant to provide more time to examine a potential causal...
View ArticleCorcept plots future for ALS drug that flunked Phase 2, citing survival analysis
Corcept Therapeutics is piecing together a path forward for an experimental drug that failed a mid-stage ALS study after new data showed the treatment boosted survival outcomes. Back in December, the...
View ArticleSchott Pharma's €100M+ Hungary expansion; Antheia’s $56M Series C raise
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Schott Pharma is investing over €100 million ($114 million) to expand...
View ArticleGenerics giant Teva turns to branded drugs R&D for its future
NEW YORK — A decade ago, Teva Pharmaceutical nearly sank its century-old business when it struck a $40.5 billion deal. In July 2015, Teva announced it would buy Allergan's generics business ...
View ArticleTrump health appointees pledge support for cell and gene therapies at FDA
HHS Secretary Robert F. Kennedy Jr. joined the heads of the FDA, NIH and CMS in backing the advancement of cell and gene therapies on Thursday, highlighting a recent success story for ...
View ArticleCMS talks health tech
On Tuesday, the Centers for Medicare and Medicaid Services convened a bunch of health tech leaders for a listening session on its recent request for information about improving health IT ...
View ArticleMakary looks at ways to speed FDA approvals, talks about cutting user fees
FDA Commissioner Marty Makary said that he is open to reworking the drug approval process in ways that will be advantageous to the biopharma industry. In a series of recent talks, Makary has said he ...
View ArticleChina is closing in on US biotech, Harvard report warns
Among five tech sectors, China has the most immediate opportunity to overtake the US in biotechnology. That’s according to a report released on Thursday by the Harvard Belfer Center for Science ...
View ArticleOmada Health prices IPO at $19 a share, $1.1B valuation
Omada Health priced its shares in the middle of its indicated range at $19 each, valuing it at around $1.1 billion. It plans to start trading Friday on the Nasdaq under the ticker OMDA, becoming ...
View ArticleGSK taps Sanofi vet to lead vaccine R&D; Bristol Myers names head of...
→ GSK has made a key hire for a crucial part of its business, appointing Sanjay Gurunathan as global head of vaccines and infectious disease R&D. Over the course of 25 years with Sanofi, Gurunathan...
View ArticleBiopharma leaders carving a path for the industry’s LGBTQ+ community
Welcome to the fourth edition of Endpoints News’ special report on scientists, executives, investors and other stakeholders in the biopharma’s LGBTQ+ community. Every year since the inaugural report in...
View ArticleOtsuka details positive Phase 3 IgAN data as it awaits FDA decision
Otsuka has shared the specifics of a late-stage win for a rare kidney disease treatment that’s on track to become its first wholly-owned product to be sold in the US. The biotech’s monoclonal antibody,...
View ArticleAt a crossroads, biotechs are passing on reverse mergers in 2025
Reverse mergers have once again lost their luster. An alternative to going public, reverse mergers once carried a negative stigma. But the financing vehicle gained newfound attention in recent years as...
View ArticleUS pharma imports normalize after March tariff stockpiling
After a rush of imports into the US in March as pharma companies sought to get ahead of the Trump administration’s tariffs, trading patterns have fallen back to normal, according to US government data...
View ArticleMIT scientists debut AI model Boltz-2 that predicts drug binding affinity
A trio of young MIT scientists unveiled a new AI bio model on Friday that predicts binding affinities, a major challenge to discovering drugs that has previously evaded progress with other AI methods....
View ArticleKelun's $250M PIPE; Valneva moves chikungunya vaccine to Phase 3 for kids
Plus, news about Trevi Therapeutics: Kelun Biotech’s $250M stock sale: The Sichuan company upsized its PIPE from $200 to $250 million and included investors from around the globe, including sovereign...
View ArticleIs there still hope for Summit's cancer drug buried in the data?
Although Summit Therapeutics didn’t present any data at ASCO's annual meeting, it still dominated the conversation at McCormick Place in Chicago. The company put out a press release the same Friday...
View ArticleUpdated: Omada Health rose 21% in its public market debut
Omada Health ended its first day of trading up 21% in a strong signal for the second digital health company to break into the public market this year. The virtual chronic care company's stock ...
View ArticleEMA considers serious eye condition a ‘very rare’ side effect of semaglutide
The European Medicines Agency said Friday that the product information for Novo Nordisk’s Ozempic and Wegovy should be updated to list a serious eye condition as a “very rare” side effect. A
View Article